Auer J, Oliver D O, Winearls C G
Renal Unit, Churchill Hospital, Oxford, UK.
Scand J Urol Nephrol Suppl. 1990;131:61-5.
In June 1986, eight haemodialysis patients, seven male, one female, entered a pilot trial of recombinant human erythropoietin (EPO) at the Churchill Hospital Renal Unit. Six patients completed the Nottingham Health Profile (NHP) before starting EPO therapy, in order to assess quality of life, and were retested when haemoglobin level reached 120 g/l. A further test was given at one year. Statistically significant improvements were seen in the areas of Energy and Emotional Wellbeing. In the subsequent UK trial, involving previously transfusion dependent patients from nine centres, the pre and post treatment NHP scores of a further 18 patients have been assessed. Highly significant improvements were found in Energy, Physical Mobility (p less than 0.005) and in Emotional Wellbeing (p less than 0.002). Improvements which did not reach significance were found in the areas of Sleep, Social Isolation and Pain problems. An increase in appetite, and less sensitivity to cold were noted by over one third of patients. Problems with Employment, Looking after the Home, and Relationships were greatly reduced. We conclude that early findings show EPO treatment to improve not only the haemoglobin levels, but also the quality of life of haemodialysis patients with the anaemia of end stage renal failure.
1986年6月，8名血液透析患者（7名男性，1名女性）进入了丘吉尔医院肾脏科进行的重组人促红细胞生成素（EPO）的试点试验。6名患者在开始EPO治疗前完成了诺丁汉健康量表（NHP），以评估生活质量，并在血红蛋白水平达到120 g/l时再次进行测试。一年后又进行了一次测试。在精力和情绪健康方面出现了具有统计学意义的改善。在随后的英国试验中，涉及来自9个中心的先前依赖输血的患者，对另外18名患者治疗前后的NHP评分进行了评估。在精力、身体活动能力（p<0.005）和情绪健康（p<0.002）方面发现了高度显著的改善。在睡眠、社交孤立和疼痛问题方面发现的改善未达到显著水平。超过三分之一的患者注意到食欲增加，对寒冷的敏感度降低。就业、照顾家庭和人际关系方面的问题大大减少。我们得出结论，早期研究结果表明，EPO治疗不仅能提高血红蛋白水平，还能改善终末期肾衰竭贫血血液透析患者的生活质量。
